Literature DB >> 20060356

Downregulation of CD9 protein expression is associated with aggressive behavior of oral squamous cell carcinoma.

Marcilei Eliza Cavicchioli Buim1, Silvia Vanessa Lourenço, Kátia Candido Carvalho, Roberta Cardim, Cláudia Pereira, André Lopes Carvalho, José Humberto Fregnani, Fernando Augusto Soares.   

Abstract

Squamous cell carcinoma of the oral cavity (OSCC) is a malignancy characterized by a high degree of local aggression and metastasis to cervical lymph nodes. Tetraspanins are proteins with functional roles in a wide array of cellular processes and are reported to be associated with tumor progression. The present study investigated the expression of the CD9, CD37, CD63, CD81 and CD82 tetraspanins in OSCC using immunohistochemistry (IHC) and quantitative Real Time-PCR (qRT-PCR). Tissue microarray (TMA) analysis of samples from 179 cases of OSCC and 10 normal samples oral mucosa were evaluated immunomorphologically. We analyzed CD9 and CD82 expression by qRT-PCR in 66 OSCC cases and 4 normal samples of oral mucosa. Expression of CD63, CD37 and CD81 was not detected in the samples studied. CD82 was downregulated or negative in 127 of 179 (80%) specimens; no correlation was observed between CD82 expression, clinicopathological parameters, disease-free survival and 5-year overall survival. CD9 expression was downregulated or negative in 75 of 129 (42%) OSCC samples. Loss of CD9 expression in OSCC samples correlated with the incidence of lymph node metastasis (p=0.017). Disease-free survival and the 5-year overall survival of patients with downregulated or negative CD9 expression were significantly lower than in patients with positive CD9 expression (p=0.010 and p=0.071, respectively). No correlation was found between CD9 or CD82 expression and clinicopathological parameters by qRT-PCR. Our results suggest that the downregulation or lack of expression of the CD9 protein might indicate a more aggressive of OSCC. (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20060356     DOI: 10.1016/j.oraloncology.2009.11.009

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  14 in total

1.  Balancing yield, purity and practicality: a modified differential ultracentrifugation protocol for efficient isolation of small extracellular vesicles from human serum.

Authors:  Scott M Langevin; Damaris Kuhnell; Melissa A Orr-Asman; Jacek Biesiada; Xiang Zhang; Mario Medvedovic; Hala Elnakat Thomas
Journal:  RNA Biol       Date:  2019-01-13       Impact factor: 4.652

2.  Morphological and molecular features of oral fluid-derived exosomes: oral cancer patients versus healthy individuals.

Authors:  Ayelet Zlotogorski-Hurvitz; Dan Dayan; Gavriel Chaushu; Tuula Salo; Marilena Vered
Journal:  J Cancer Res Clin Oncol       Date:  2015-06-27       Impact factor: 4.553

3.  GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker.

Authors:  Kátia C Carvalho; Isabela W Cunha; Rafael M Rocha; Fernanda R Ayala; Mariana M Cajaíba; Maria D Begnami; Rafael S Vilela; Geise R Paiva; Rodrigo G Andrade; Fernando A Soares
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 4.  Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies.

Authors:  S Detchokul; E D Williams; M W Parker; A G Frauman
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

5.  Tetraspanins CD9 and CD151, epidermal growth factor receptor and cyclooxygenase-2 expression predict malignant progression in oral epithelial dysplasia.

Authors:  P Nankivell; H Williams; C McConkey; K Webster; A High; K MacLennan; B Senguven; P Rabbitts; H Mehanna
Journal:  Br J Cancer       Date:  2013-11-07       Impact factor: 7.640

6.  Down-regulation of CD9 by methylation decreased bortezomib sensitivity in multiple myeloma.

Authors:  Xiaotong Hu; Han Xuan; Huaping Du; Hao Jiang; Jinwen Huang
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

7.  Assessment of TSPAN Expression Profile and Their Role in the VSCC Prognosis.

Authors:  Kelly Pedrozo Ferreira; Bruna Cristine de Almeida; Laura Gonzalez Dos Anjos; Glauco Baiocchi; Fernando Augusto Soares; Rafael Malagoli Rocha; Edmund Chada Baracat; Andrey Senos Dobroff; Katia Candido Carvalho
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

8.  CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma.

Authors:  Vishwa Jeet Amatya; Yukio Takeshima; Keisuke Aoe; Nobukazu Fujimoto; Toshihiro Okamoto; Taketo Yamada; Takumi Kishimoto; Chikao Morimoto; Kouki Inai
Journal:  Oncol Rep       Date:  2012-10-31       Impact factor: 3.906

9.  Expression and clinicopathological significance of CD9 in gastrointestinal stromal tumor.

Authors:  Hongxin Yang; Chaoyong Shen; Bo Zhang; Haining Chen; Zhixin Chen; Jiaping Chen
Journal:  J Korean Med Sci       Date:  2013-09-25       Impact factor: 2.153

Review 10.  Should EMT of Cancer Cells Be Understood as Epithelial-Myeloid Transition?

Authors:  Henning M Schramm
Journal:  J Cancer       Date:  2014-01-15       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.